Skip to content

Legend Biotech

US · LEGN #2374 by market cap Listed 2020
15.25 -0.85 -5.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/9/11
  • Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $61
    Market Newswire · 2026/11/11
  • Rating change
    Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $68
    Market Newswire · 2026/11/6
  • Rating change
    UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28
    Market Newswire · 2026/8/14
  • Rating change
    A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65
    Market Newswire · 2026/8/12
  • Rating change
    Piper Sandler Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $64
    Market Newswire · 2026/11/5
  • Rating change
    UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $24
    Market Newswire · 2026/10/2
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)
    TipRanks · 2026/8/12
  • Rating change
    UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $24
    Market Newswire · 2026/10/28
  • Rating change
    Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $68
    Market Newswire · 2026/10/13
  • Rating change
    Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74
    Market Newswire · 2026/9/11
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/8/12
  • Rating change
    RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $56
    Market Newswire · 2026/10/8
  • Rating change
    A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48
    Market Newswire · 2026/8/13
  • A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $25 to $65
    Market Newswire · 2026/11/12
  • Evercore Initiates Legend Biotech(LEGN.US) With Hold Rating, Announces Target Price $20
    Market Newswire · 2026/11/14
  • Rating change
    Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $38.09
    Market Newswire · 2026/10/14
  • Rating change
    J.P. Morgan Maintains Legend Biotech(LEGN.US) With Hold Rating, Cuts Target Price to $33
    Market Newswire · 2026/10/9
  • H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/11/11
  • Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $43
    Market Newswire · 2026/11/12
  • Rating change
    J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35
    Market Newswire · 2026/7/13
  • Rating change
    RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59
    Market Newswire · 2026/7/27
  • H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/10/30
  • Rating change
    Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5
    Market Newswire · 2026/7/16
  • Core product sales performance reaffirmed; when will Legend Biotech (LEGN.US) reverse the "strong in the short term, weak in the medium term" stock price structure?
    Zhitong Finance · 2026/10/15

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Legend Biotech discussion 0 comments

Add a comment